Moderna to build mRNA facility in Africa
The aim is to first produce Covid-19 vaccines and then add more vaccines in the years to come
The aim is to first produce Covid-19 vaccines and then add more vaccines in the years to come
The preclinical study provides evidence for strongly improved immune responses with second-generation mRNA backbone jointly developed by CureVac and GSK compared to CureVac’s first-generation mRNA backbone
The collaboration will support Canada with direct access to rapid pandemic response capabilities
Moderna's updated COVID-19 mRNA vaccine will be available for the 2025-2026 vaccination season, pending a European Commission authorization decision
Spikevax is now approved for all individuals aged 6 months through 64 years at increased risk for COVID-19 disease
Capstan's lead asset, CPTX2309, is a targeted lipid nanoparticle (tLNP) that delivers an mRNA encoding an anti-CD19 chimeric antigen receptor (CAR) to CD8-expressing cytotoxic T cells in vivo
BioNTech and Bristol Myers Squibb will jointly execute a broad clinical development program to evaluate and advance BNT327 across numerous solid tumor types
In light of the contributions of these three institutes, it was decided to organize a CSIR Startup Conclave in Hyderabad. The event, scheduled for April 22–23, 2025
Lonza’s new simplified and streamlined operating model is designed to support its One Lonza vision and strategy
Subscribe To Our Newsletter & Stay Updated